These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 25667169)

  • 21. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections.
    Younis W; Thangamani S; Seleem MN
    Curr Pharm Des; 2015; 21(28):4106-11. PubMed ID: 25961308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.
    Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.
    MacVane SH
    J Intensive Care Med; 2017 Jan; 32(1):25-37. PubMed ID: 26772199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New antibiotics - standstill or progress].
    Rademacher J; Welte T
    Med Klin Intensivmed Notfmed; 2017 Apr; 112(3):206-213. PubMed ID: 28314920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's new and not so new on the antimicrobial horizon?
    French GL
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():19-29. PubMed ID: 19040463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of the ESKAPE pathogens.
    Pendleton JN; Gorman SP; Gilmore BF
    Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.
    Guay DR
    Pharmacotherapy; 2004 Jan; 24(1):58-68. PubMed ID: 14740788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study.
    Raymond J; Nordmann P; Doit C; Vu Thien H; Guibert M; Ferroni A; Aujard Y
    Pediatrics; 2007 Apr; 119(4):e798-803. PubMed ID: 17403822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New agents in development for the treatment of bacterial infections.
    Abbanat D; Morrow B; Bush K
    Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic considerations in the treatment of multidrug-resistant (MDR) pathogens: a case-based review.
    Reddy P; Chadaga S; Noskin GA
    J Hosp Med; 2009 Jul; 4(6):E8-15. PubMed ID: 19670375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.